Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Mesothelioma, Malignant 2Lung Neoplasms 2Esophageal Neoplasms 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Small Cell Lung Carcinoma 1Pleural Effusion, Malignant 1Pancreatic Neoplasms 1Pancreatic Adenocarcinoma Metastatic 1Neoplasms 1Neoplasm Metastasis 1Metastatic Pancreatic Adenocarcinoma 1Esophageal Squamous Cell Carcinoma 1Colorectal Cancer Metastatic 1Colonic Neoplasms 1

Interventions

Gemcitabine 6Fluorouracil 5Leucovorin 4Irinotecan 3Albumin-Bound Paclitaxel 3pembrolizumab 2irinotecan sucrosofate 2Oxaliplatin 24-fluorobenzoyl-TN-14003 2zolbetuximab 1regorafenib 1olaparib 1ibrutinib 1beta-D-glucosylisophosphoramide mustard 1adavosertib 1Tetrahydrouridine 1Telemedicine 1Taxes 1Practice Guidelines as Topic 1Paclitaxel 1PEGPH20 1Erlotinib Hydrochloride 1Drug Therapy 1Docetaxel 1Decitabine 1Counseling 1Cisplatin 1Capecitabine 1BKT140 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Metastatic Pancreatic Adenocarcinoma × Decitabine × Gastrointestinal × Clear all
NCT02847000 2019-01-09

p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Pancreatic Cancer

Case Comprehensive Cancer Center

Phase EARLY_PHASE1 Completed
13 enrolled
Gastrointestinal

Metastatic Pancreatic Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡